Phase 1 Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome

Trial Profile

Phase 1 Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Miransertib (Primary)
  • Indications Proteus syndrome
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 05 Mar 2018 According to an ArQule media release, data anticipated in 2018.
    • 07 Feb 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
    • 07 Feb 2018 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top